Skip to main content

Advertisement

SpringerLink
Log in

Idiosyncratic Drug-Induced Liver Injury: A Clinical Update

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Drug-induced liver injury (DILI) is a rare but potentially devastating adverse drug reaction. Its presentation can range from asymptomatic elevation in liver biochemistries to fulminant liver failure. Over the past decade, clinical and research interest in the field of idiosyncratic DILI has been intense, and several new findings have been reported. In this article, we provide an update on implicated agents, clinical features, outcomes, and the results of recently reported genetic studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Larson AM, Polson J, Fontana RJ, et al.: Acetaminophen-induced acute liver failure: results of a United States multi-center, prospective study. Hepatology 2005, 42:1364–1372.

    Article  CAS  PubMed  Google Scholar 

  2. Larrey D: Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002, 22:145–155.

    Article  CAS  PubMed  Google Scholar 

  3. • Chalasani N, Fontana RJ, Herbert L, et al.: Causes, clinical features, and outcomes from a prospective study of drug-Induced liver injury in the United States. Gastroenterology 2008, 135:1924–1934. This paper reports preliminary findings of an ongoing study (nearly 800 patients enrolled) conducted in the United States. This study confirmed that DILI with jaundice carries high mortality. A surprising finding of this study is that about 0.5% of enrolled patients had unsuspected acute hepatitis C masquerading as DILI.

    Article  PubMed  Google Scholar 

  4. Andrade RJ, Lucena I, Fernandez C, et al: Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129:512–521.

    PubMed  Google Scholar 

  5. Ibanez L, Perez E, Vidal X, Laporte JR: Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002, 37:592–600.

    Article  PubMed  Google Scholar 

  6. Alla V, Abraham J, Siddique J, et al.: Autoimmune liver disease triggered by statins: report of 3 instances and review of literature. J Clin Gastroenterol 2006, 40:757–761.

    Article  CAS  PubMed  Google Scholar 

  7. Lim JR, Fraught PR, Chalasani N, Molleston J: Severe liver injury after starting atomoxetine (Strattera) in two children. J Pediatrics 2006, 148:831–834.

    Article  Google Scholar 

  8. Bjornsson E, Talwalkar J, Treeprasertsuk S, et al.: Drug induced Autoimmune Hepatitis: clinical characteristics and prognosis. Hepatology 2010, 51:2040–2048.

    PubMed  Google Scholar 

  9. • Chalasani N, Bjornsson E: Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010, 138:2246–2259. This recently published review article summarizes nongenetic and genetic risk factors for developing idiosyncratic DILI.

    Article  CAS  PubMed  Google Scholar 

  10. Chalasani N: Statin hepatotoxicity: focus on statin usage in nonalcoholic fatty liver disease. Hepatology 2005, 41:690–695.

    Article  CAS  PubMed  Google Scholar 

  11. Cohen D, Anania F, Chalasani N: Report of the liver expert panel. Statin Safety Task Force, National Lipid Association. Am J Cardiol 2006, 97(Suppl):77C–81C.

    Article  CAS  PubMed  Google Scholar 

  12. Chalasani N, Aljadhey H, Kesterson J, et al.: Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004, 126:1287–1292.

    Article  CAS  PubMed  Google Scholar 

  13. Vuppalanchi R, Teal E, Chalasani N: Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005, 329:62–65.

    Article  PubMed  Google Scholar 

  14. Targher G, Day CP, Bonor E: Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363:1341–1350.

    Article  CAS  PubMed  Google Scholar 

  15. Browning JD: Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006, 44:466–471.

    Article  CAS  PubMed  Google Scholar 

  16. Nunez M: Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010, 52:1143–1155.

    Article  CAS  PubMed  Google Scholar 

  17. Park WB, Kim W, Lee KL, et al.: Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. J Infect 2010, 61:323–329.

    Article  PubMed  Google Scholar 

  18. Uetrecht J: Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007, 47:513–539.

    Article  CAS  PubMed  Google Scholar 

  19. • Lammert C, Einarsson S, Saha C, et al.: Relationship between daily dose of oral medications and idiosyncratic drug induced liver injury (DILI): search for signals. Hepatology 2008, 47:2003–2009. This study showed that oral compounds administered at doses ≥50 mg/day are at higher risk to cause hepatotoxicity than those given at lower doses. This study consisted of several datasets that exhibited a similar pattern of dose-dependency.

    Article  CAS  PubMed  Google Scholar 

  20. Lammert C, Niklasson A, Bjornsson E, Chalasani N: Oral medications with significant hepatic metabolism are at higher risk for hepatic adverse events. Hepatology 2010, 51:615–620.

    CAS  PubMed  Google Scholar 

  21. Andrade JR, Lucena MI, Kaplowitz N, et al.: Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006, 44:1581–1588.

    Article  CAS  PubMed  Google Scholar 

  22. Fontana RJ, Watkins PB, Bonkovsky HL, et al.: Rationale, design and conduct of the drug induced liver injury network prospective study. Drug Safety 2009, 32:55–68.

    Article  CAS  PubMed  Google Scholar 

  23. Björnsson E, Kalaitzakis E, Olsson R: The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007, 25:1411–1421.

    Article  PubMed  Google Scholar 

  24. Benichou C: Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990, 11:272–276.

    Article  CAS  PubMed  Google Scholar 

  25. Benichou C, Danan G, Falhault A, et al.: Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993, 45:1331–1336.

    Article  Google Scholar 

  26. Rockey DC, Seeff LB, Rochon J, et al. for the Drug-Induced Liver Injury Network: A structured assessment process to assign causality in drug induced liver injury. Hepatology 2010, 51:2117–2126.

    PubMed  Google Scholar 

  27. Papay JI, Clines D, Rafi R, et al.: Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol 2009, 54: 84–90.

    Article  CAS  PubMed  Google Scholar 

  28. Dalton HR, Fellows HJ, Stableforth W, et al.: The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007, 26:1429–1435.

    Article  CAS  PubMed  Google Scholar 

  29. Kaplowitz N: Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005, 4:489–499.

    Article  CAS  PubMed  Google Scholar 

  30. •• Kindmark A, Jawaid A, Harbron CG, et al.: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008, 8:186–195. This article describes the first genome-wide association study conducted to explore the genetic basis of DILI in humans. Ximelagatran, a compound with great promise, was abandoned because of idiosyncratic DILI. This study showed a strong relationship between HLA DRB1*07 and HLA DQA1*02 and liver injury from ximelagatran.

    Article  CAS  PubMed  Google Scholar 

  31. •• Daly AK, Donaldson PT, Bhatnagar P, et al.: HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 41:816–821. A landmark article published by the International SAE consortium showed an exceptionally strong relationship between HLA B*5701 and flucloxacillin hepatotoxicity. This compound is not available in the United States.

    Article  CAS  PubMed  Google Scholar 

  32. The International Serious Adverse Events Consortium DILI Genetics Research Update: Drug-induced liver injury getting the medicine and science together. Presented at the Food and Drug Administration/American Association for the Study of Liver Diseases/Pharmaceutical Research and Manufacturers of America (FDA/AASLD/PhRMA) meeting. Silver Spring, MD; March 24, 2010. Available at http://www.aasld.org/conferences/Documents/PresentationLibrary/2010Hepatoxicity_SessionII_Nelson.pdf. Accessed October 2010.

  33. US Department of Health and Human Services, Food and Drug Administration: Guidance for industry: drug-induced liver injury: premarketing clinical evaluation. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf. Accessed October 2010.

  34. Bjornsson E: Drug induced liver injury: Hy’s rule revisited. Clin Pharmacol Ther 2006, 79:521–528.

    Article  PubMed  Google Scholar 

  35. Lewis JH: Hy’s law, the “rezulin rule,” and other predictors of severe drug-induced hepatotoxicity; putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf 2006, 15:221–229.

    Article  CAS  PubMed  Google Scholar 

  36. Lee WM, Hynan LS, Rossaro L, et al.: Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009, 137:856–864.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

Conflicts of interest: H. Maddur—none; N. Chalasani—consulting fees from KaroBio, Amylin, Gilead, Genentech, Teva, Norgine, Ockham Development (general consulting related to clinical trials), Abbott, Salix, Phenomix, Medpace, AstraZeneca, Gilead, and Lilly.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Indiana University School of Medicine, RG 4100, 1050 Wishard Boulevard, Indianapolis, IN, 46202, USA

    Haripriya Maddur & Naga Chalasani

Authors
  1. Haripriya Maddur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naga Chalasani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naga Chalasani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maddur, H., Chalasani, N. Idiosyncratic Drug-Induced Liver Injury: A Clinical Update. Curr Gastroenterol Rep 13, 65–71 (2011). https://doi.org/10.1007/s11894-010-0154-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-010-0154-8

Keywords

Search

Navigation